Bacillus Calmette-Guérin (BCG)
Sponsors
Merck Sharp & Dohme LLC, Aeras, Memorial Sloan Kettering Cancer Center, Boston Children's Hospital, Noah Hahn, M.D.
Conditions
Bladder CancerHigh Risk Non-muscle invasive bladder cancerHigh Risk SuperficialNewborn Vaccine ImmunogenicityNon-Muscle Invasive Bladder Cancer (NMIBC)TuberculosisUrinary Bladder NeoplasmsUrothelial Carcinoma
Phase 1
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
RecruitingNCT03317158
Start: 2017-11-21End: 2026-12-31Target: 55Updated: 2025-01-30
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
Active, not recruitingNCT04179162
Start: 2019-11-22End: 2026-11-30Updated: 2025-06-13
Phase 2
Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents
CompletedNCT02075203
Start: 2014-02-28End: 2017-10-06Updated: 2019-09-04
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
CompletedNCT02281383
Start: 2014-10-31End: 2022-02-24Updated: 2023-02-08
Phase II Study of H4:IC31 and BCG revaccination in Healthy Adolescents (040-404)
Active, not recruitingPACTR201512001069358
Start: 2014-02-18Target: 990Updated: 2026-01-27
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Active, not recruitingNCT03504163
Start: 2018-06-27End: 2026-04-30Updated: 2025-11-06
Phase 3
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
TerminatedNCT04149574
Start: 2020-01-15End: 2023-10-31Updated: 2025-09-16
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)
Active, not recruitingCTIS2022-501817-29-00
Start: 2018-11-27Target: 559Updated: 2025-10-29